Quantitative Volumetric Comparison of Pulmonary Thrombus Reduction between Direct Oral Anticoagulant and Vitamin K Antagonist Treatment in Acute Phase of Symptomatic Patients

Quantitative Volumetric Comparison of Pulmonary Thrombus Reduction between Direct Oral Anticoagulant and Vitamin K Antagonist Treatment in Acute Phase of Symptomatic Patients - Volumetric Comparison of Pulmonary Thrombus Reduction between DOAC and VKA Treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027351

Enrollment

Registered

2017-05-15

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary thromboembolism

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic patients with pulmonary thromboembolism who were hospitalized in a single cardiovascular institute between February 2015 and December 2016.

Exclusion criteria

Exclusion criteria: 1. Patients with unstable hemodynamics with massive thromboembolism. 2. Patients with active bleeding. 3. Patients with plenty of deep vein thrombus who needed thrombolytic therapy.

Design outcomes

Primary

Measure	Time frame
Reduction rate of pulmonary thrombus	—

Countries

Japan

Contacts

Public ContactKentaro Jujo

Tokyo Women's Medical University Cardiology

juken1123@mac.com+81333538111

Outcome results